Calls
2
u/LectureForsaken6782
Reddit r/ValueInvesting
Win Rate
50.0%
return
+4.1%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Aug 02
$25.87
+13.8%
ACAD has zero crippling debt, high margins, and double-digit revenue growth. Solid commercial execution (Nuplazid/Daybue) meets strict value and growth criteria. The author holds a position, noting it surprisingly passes all strict biotech hurdles. Clinical trial risks or regulatory hurdles typical of the biotech sector.
ACAD has zero crippling debt, high margins, and double-digit revenue growth. Solid commercial execution (Nuplazid/Daybue) meets strict value and growth criteria. The author holds a position, noting it surprisingly passes all strict biotech hurdles. Clinical trial risks or regulatory hurdles typical of the biotech sector.
Pharma & Biotech
Long
Aug 02
$96.88
-5.6%
DECK boasts ~55.8% gross margins, ~17% YoY sales growth, and a PEG < 1.5. Strong pricing power (HOKA/UGG) and growth at a reasonable valuation make it a compelling hold. The author holds a position and it perfectly passed the strict 4-point screener. Consumer discretionary spending drops or fashion trends shift away from its brands.
DECK boasts ~55.8% gross margins, ~17% YoY sales growth, and a PEG < 1.5. Strong pricing power (HOKA/UGG) and growth at a reasonable valuation make it a compelling hold. The author holds a position and it perfectly passed the strict 4-point screener. Consumer discretionary spending drops or fashion trends shift away from its brands.
Retail & Mobility
Showing 2 of 2 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/LectureForsaken6782 has 2 trade ideas tracked on Buzzberg across 2 tickers since August 2026. Most covered: DECK, ACAD.
